Hemostats Market by Type (Collagen-Based Hemostats, Combination Hemostats, Gelatin-Based Hemostats), Formulation (Matrix & Gel Hemostats, Powder Hemostats, Sheet & Pad Hemostats), Application - Global Forecast 2024-2030

Hemostats Market by Type (Collagen-Based Hemostats, Combination Hemostats, Gelatin-Based Hemostats), Formulation (Matrix & Gel Hemostats, Powder Hemostats, Sheet & Pad Hemostats), Application - Global Forecast 2024-2030


The Hemostats Market size was estimated at USD 3.23 billion in 2023 and expected to reach USD 3.42 billion in 2024, at a CAGR 5.65% to reach USD 4.75 billion by 2030.

The hemostats are a range of medical devices and products designed to control, prevent, and stop bleeding during surgical procedures and traumatic injuries. These devices play an important role in managing blood loss and facilitate proper tissue healing while reducing the risk of complications. Hemostats have applications in numerous surgical specialties, including cardiovascular surgery, general surgery, orthopedic surgery, neurosurgery, gynecologic surgery, and dental surgery. The growing occurrence of chronic diseases among an aging population drives the demand for surgeries that necessitate effective blood loss management solutions, consequently expanding the utilization of diverse hemostatic agents. Additionally, increasing inclination toward minimally invasive procedures with rising investments by government bodies and healthcare organizations to improve surgical infrastructure is raising the usage of hemostats. High R&D costs associated with developing breakthrough products and a high risk of contamination with hemostats hamper market growth. The increasing development of biologically compatible hemostats by market vendors that minimize adverse effects while providing effective bleeding control is expected to create opportunities for market growth.

Regional Insights

The growing number of surgical procedures with the rising availability of advanced healthcare facilities, especially across the U.S., Canada, and Brazil, are expanding the growth of the hemostats market in the Americas. According to the American Society of Plastic Surgeons, in 2022, a total of 1,017,003 reconstructive surgeries were performed, necessitating the use of hemostats. The emerging trend of medical tourism across Canada, Dubai, Singapore, Japan, and the UK is expanding the number of minimally invasive surgical procedures, thereby creating a platform for the hemostats market. According to the Medical Tourism Index survey (MTA), Canada is one of the preferred destinations, attracting around 14 million Americans from other nations. Ongoing advancements in healthcare infrastructure and technologies across European countries, with constant support from regulatory bodies such as the European Medicines Agency (EMA) on expanding the manufacturing of medical devices and healthcare infrastructure, are bolstering the European market. The Middle East & Africa region presents promising growth opportunities due to increasing healthcare expenditure and government initiatives towards modernizing healthcare infrastructure. Countries, including Saudi Arabia, the United Arab Emirates, and South Africa, are witnessing a surge in the need for effective hemostatic solutions with the rising number of surgical interventions. Moreover, increased government funding to expand the manufacturing of medical devices domestically across India, Australia, China, and Japan and increased awareness associated with minimally invasive surgeries are expected to bolster market growth in Asia-Pacific.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Hemostats Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Prevalence of chronic disorders with increasing need for surgical interventions
Growing inclination toward minimally invasive surgeries

Market Restraints

Rising incidences of product recalls

Market Opportunities

Rise of biopolymer-based disposable hemostats
Integration of nanotechnology to create more efficient and targeted hemostats

Market Challenges

Risk of infection and cross contamination associated with the use of hemostats tools and reagents

Market Segmentation Analysis

Type: Expanding the use of combination hemostats owing to their enhanced effectiveness in minimizing bleeding
Formulation: Growing potential of powder hemostats for controlling and preventing bleeding during surgical intervention
Application: Significant role of hemostats in cardiovascular surgeries to prevent blood loss and ensure successful outcomes

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Hemostats Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Hemostats Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+ Hemostatic Device Usage in Cardiac Surgical Procedures

Teleflex Incorporated received clearance from the U.S. Food and Drug Administration (FDA) for the QuikClot Control+ Hemostatic Device. This device is now approved for use in cardiac surgical procedures to address mild and moderate bleeding, as well as bone surface bleeding after a sternotomy.

Baxter Launches PERCLOT Absorbable Hemostatic Powder

Baxter International Inc. introduced PERCLOT Absorbable Hemostatic Powder in the U.S., a passive hemostatic powder designed for patients with intact coagulation. PERCLOT's granules effectively absorb water, forming a gelled adhesive matrix that acts as a mechanical barrier against further bleeding. This process promotes the accumulation of platelets, red blood cells, and coagulation proteins, aiding in the hemostatic process.

Artivion Gains FDA Approval for PerClot, Starts Transfer to Baxter

Artivion, Inc. has received FDA premarket application approval for its absorbable hemostatic system, PerClot. In July 2021, Baxter acquired full ownership of PerClot through a sale agreement. The FDA approval of PerClot, Artivion represents a significant step ahead in optimizing patient care by addressing intraoperative bleeding.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Hemostats Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Hemostats Market, highlighting leading vendors and their innovative profiles. These include A.R. Medicom, Inc., ACTEON Group, Advamedica Inc., Advanced Medical Solutions Group PLC, Advin Health Care, Aegis Lifesciences Private Limited, Argon Medical Devices, B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, Betatech Medical, Convatec Group PLC, Cook Group Incorporated, Cortis Medtech Pvt Ltd, Cotran Corporation, Dolphin Sutures by Futura Surgicare Pvt. Ltd., Dynarex Corporation, Gelita AG, Hangzhou Singclean Medical Products Co.,Ltd., Healthium Medtech Ltd, Hemostasis, LLC, Integra LifeSciences Holdings Corporation, Johnson & Johnson Services, Inc., Medcura, Inc., Medline Industries, LP, Medprin Biotech GmbH, Medtronic PLC, Meril Life Sciences Pvt. Ltd., Olympus Corporation, Pfizer Inc., Rousselot BV by Darling Ingredients International Holding B.V., Royal DSM, Shilpa Medicare Limited, Stapleline Medizintechnik GmbH, Stryker Corporation, SYMATESE, Teleflex Incorporated, Terumo Corporation, Zhejiang Perfectseal New Material Technology Co., Ltd., and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Hemostats Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Collagen-Based Hemostats
Combination Hemostats
Gelatin-Based Hemostats
Oxidized Regenerated Cellulose-Based Hemostats
Thrombin-Based Hemostats
Formulation
Matrix & Gel Hemostats
Powder Hemostats
Sheet & Pad Hemostats
Sponge Hemostats
Application
Cardiovascular Surgery
General Surgery
Gynecological Surgery
Neurological Surgery
Orthopedic Surgery
Reconstructive Surgery
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic disorders with increasing need for surgical interventions
5.1.1.2. Growing inclination toward minimally invasive surgeries
5.1.2. Restraints
5.1.2.1. Rising incidences of product recalls
5.1.3. Opportunities
5.1.3.1. Rise of biopolymer-based disposable hemostats
5.1.3.2. Integration of nanotechnology to create more efficient and targeted hemostats
5.1.4. Challenges
5.1.4.1. Risk of infection and cross contamination associated with the use of hemostats tools and reagents
5.2. Market Segmentation Analysis
5.2.1. Type: Expanding the use of combination hemostats owing to their enhanced effectiveness in minimizing bleeding
5.2.2. Formulation: Growing potential of powder hemostats for controlling and preventing bleeding during surgical intervention
5.2.3. Application: Significant role of hemostats in cardiovascular surgeries to prevent blood loss and ensure successful outcomes
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Hemostats Market, by Type
6.1. Introduction
6.2. Collagen-Based Hemostats
6.3. Combination Hemostats
6.4. Gelatin-Based Hemostats
6.5. Oxidized Regenerated Cellulose-Based Hemostats
6.6. Thrombin-Based Hemostats
7. Hemostats Market, by Formulation
7.1. Introduction
7.2. Matrix & Gel Hemostats
7.3. Powder Hemostats
7.4. Sheet & Pad Hemostats
7.5. Sponge Hemostats
8. Hemostats Market, by Application
8.1. Introduction
8.2. Cardiovascular Surgery
8.3. General Surgery
8.4. Gynecological Surgery
8.5. Neurological Surgery
8.6. Orthopedic Surgery
8.7. Reconstructive Surgery
9. Americas Hemostats Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Hemostats Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Hemostats Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+ Hemostatic Device Usage in Cardiac Surgical Procedures
12.3.2. Baxter Launches PERCLOT Absorbable Hemostatic Powder
12.3.3. Artivion Gains FDA Approval for PerClot, Starts Transfer to Baxter
12.3.4. Olympus Europa SE & Co. KG Expands Endoclot Partnership with Endoclot to Launch Hemostatic Agents
12.3.5. Darling Ingredients Completes Acquisition of Brazilian Gelatin and Collagen Producer Gelnex
12.3.6. Chitosan-Based Hemostat For Controlling Severe Surgical Bleeding Gets FDA Clearance
12.3.7. Advamedica Inc Announces FDA Clearance for Ax-Surgi Surgical Hemostat
12.3.8. Medcura, Inc. Receives Breakthrough Device Designation for its LifeGel Absorbable Surgical Hemostat
12.3.9. Medtronic plc Nexpowder Endoscopic Hemostasis System Receives U.S. FDA Clearance
12.3.10. Hemostasis LLC Closes Acquisition of Fiagon Medical Technologies
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings